Here's the latest example of parsing a pharma CEO's statements about M&A: After Roche ($RHHBY) chief Severin Schwan said over the weekend that deals have to be "worth it financially," Notenstein analysts added that to their checklist of evidence against an offer for Alexion ($ALXN). Roche shares rose after the analysts' comments went public in NZZ am Sonntag. Report